TREM2 and early-onset autosomal dominant Alzheimer disease: However, in contrast to our results it has been reported that soluble TREM2 protected against amyloid-beta-driven pathology in an Alzheimer’s disease model [58], and enhanced levels of soluble TREM2 in the cerebrospinal fluid were shown to correlate with an attenuated clinical progression in Alzheimer’s patients [59].